Who Paid My Doc
Tawni Christensen
General Practice Las Vegas, NV Medical Doctor
NPI 1881640662 CMS profile 266536
5495 S Rainbow Blvd Ste 202, Las Vegas, NV 89118
General payments
$7,043
Research payments
$445,554
Ownership & investment interest
$0
Research they led as principal investigator
$1,386,105
Through program year 2025, Tawni Christensen of Las Vegas, NV is reported in the CMS Open Payments database as having received $7,043 across 84 general payments and $445,554 in research payments paid to them. Separately, studies naming them as principal investigator received $1,386,105 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 99th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,768 | 31 | |
| 2024 | General | $3,297 | 41 | |
| 2024 | Research | $445,554 | 2 | |
| 2023 | General | $80 | 2 | |
| 2022 | General | $467 | 5 | |
| 2021 | General | $432 | 5 |
Beside peers
- Tawni Christensen
- General Practice median
- Middle half of General Practice
- National median
In program year 2025, general payments to Tawni Christensen were reported at $2,768. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.
Show as a table
| Year | Tawni Christensen | General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $107 | $37–$285 | $163 |
| 2020 | $0 | $75 | $25–$213 | $114 |
| 2021 | $432 | $93 | $30–$272 | $132 |
| 2022 | $467 | $103 | $36–$279 | $149 |
| 2023 | $80 | $106 | $34–$276 | $160 |
| 2024 | $3,297 | $114 | $39–$290 | $164 |
| 2025 | $2,768 | $106 | $35–$292 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Billing to Medicare
Part B · data year 2024 · 26 billing codesPaid by Medicare
$1,400,426
Medicare patients
59
Services billed
2,426
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Arthritis | 58% | |
| Diabetes | 53% | |
| Ischemic heart disease | 53% | |
| Chronic kidney disease | 44% | |
| Heart failure | 41% | |
| Atrial fibrillation | 39% | |
| Depression | 37% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
86 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
General Practice in Nevada
Practitioners in the same specialty and state, ranked by reported value.
All General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Nevada
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.